Brinzolamide
| Code | Size | Price |
|---|
| CDX-B0424-M010 | 10 mg | £78.00 |
Quantity:
| CDX-B0424-M050 | 50 mg | £242.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
(R)-4-(Ethylamino)-3,4-dihydro-2-(3-methoxypropyl)-2H-Thieno[3,2-e]-1,2-thiazine-6-sulfonamide 1,1-dioxide; AL 4862; Azopt
Appearance:
White to beige powder.
CAS:
138890-62-7
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C12H21N3O5S3/c1-3-14-10-8-15(5-4-6-20-2)23(18,19)12-9(10)7-11(21-12)22(13,16)17/h7,10,14H,3-6,8H2,1-2H3,(H2,13,16,17)/t10-/m0/s1
InChiKey:
HCRKCZRJWPKOAR-JTQLQIEISA-N
Long Description:
Chemical. CAS: 138890-62-7. Formula: C12H21N3O5S3. MW: 383.51. Synthetic. Brinzolamide is a potent inhibitor of carbonic anhydrases (IC50=3.2nM and 45.3nM for CAII and CAIV, respectively) that lowers intraocular pressure by locally inhibiting carbonic anhydrase in the ciliary processes and suppressing aqueous humor secretion. Animal studies have found that one week of twice-daily topical ocular treatment with 2% brinzolamide significantly reduced IOP and enhanced optic nerve head blood flow.
MDL:
MFCD08067749
Molecular Formula:
C12H21N3O5S3
Molecular Weight:
383.51
Package Type:
Vial
Product Description:
Brinzolamide is a potent inhibitor of carbonic anhydrases (IC50=3.2nM and 45.3nM for CAII and CAIV, respectively) that lowers intraocular pressure by locally inhibiting carbonic anhydrase in the ciliary processes and suppressing aqueous humor secretion. Animal studies have found that one week of twice-daily topical ocular treatment with 2% brinzolamide significantly reduced IOP and enhanced optic nerve head blood flow.
Purity:
>98% (HPLC)
SMILES:
O=S(C1=CC2=C(S1)S(N(CCCOC)C[C@@H]2NCC)(=O)=O)(N)=O
Solubility Chemicals:
Soluble in DMSO (30mg/ml). Insoluble in water or ethanol.
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
(1) T. Stams, et al.; Protein Science 7, 556 (1998) | (2) P.A. Boriack-Sjodin, et al.; Protein Science 7, 2483 (1998) | (3) C.J. Ingram & R.F. Brubaker; Am. J. Ophthalmol. 128, 292 (1999) | (4) G.E. Barnes, et al.; Survey of Ophthalmol. 44, S131 (2012) | (5) H. Zheng & B. Lou; Acta Crystallogr. E Crystallogr. Commun. 72, 692 (2016) | (6) T. Nakano, et al.; Adv. Ther. 33, 1452 (2016) | (7) Y.R. Dong, et al.; Int. J. Ophthalmol. 11, 719 (2018)